ArticleWorld journal of cardiology2025
Assessing paclitaxel-coated
Article in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Sirolimus Versus Paclitaxel-Coated Balloons for Coronary Revascularization: An Updated Meta-Analysis with GRADE Assessment.Journal of the Saudi Heart Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the clinical challenges posed by drug-eluting stents, drug-coated balloons offer a promising alternative by delivering antiproliferative medications directly to the vessel wall.
aimTo compare the efficacy of paclitaxel-coated balloon (PCB) angioplasty
methodsA comprehensive literature search on PubMed, EMBASE, and Cochrane Central from inception to 5
resultsA total of nine studies with 1981 patients (949 in PCB arm and 1032 in SCB arm) were included for further quantitative analysis. The results indicated that both PCB and SCB angioplasty are effective in treating CAD, with PCB showing a greater minimal lumen diameter for DNL [mean difference: -0.11 (95% confidence interval: -0.22 to -0.01,
conclusionThis meta-analysis highlights that PCB angioplasty may offer superior angiographic outcomes compared to SCB angioplasty, specifically in achieving greater minimal lumen diameter in patients with DNL. These findings suggest that while PCB has certain advantages in terms of tissue retention and immediate efficacy, both PCB and SCB are viable options for treating ISR or DNL in CAD patients. Further large-scale studies are required to conclusively determine the long-term benefits and potential risks associated with each type of drug-coated balloons angioplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.